101 related articles for article (PubMed ID: 33161038)
1. A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model.
Guo R; Yang Y; Zhang D; Du J; Zhu X; Liu Y; Yang F; Lin J
Int J Pharm; 2021 Jan; 592():120037. PubMed ID: 33161038
[TBL] [Abstract][Full Text] [Related]
2. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
3. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
[TBL] [Abstract][Full Text] [Related]
4. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7.
Cao L; Li Q; Tong Z; Xing Y; Xu K; Yijia Wang J; Li W; Zhao J; Zhao L; Hong Z
Int J Pharm; 2020 Jan; 574():118939. PubMed ID: 31836485
[TBL] [Abstract][Full Text] [Related]
5. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
[TBL] [Abstract][Full Text] [Related]
7. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Huang L; He H; Wang K; Ma X; Chen X; Chen W; Wang X; Jiang X; Feng M
Biomed Pharmacother; 2022 Nov; 155():113659. PubMed ID: 36095959
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxin IHP25-BT with low immunogenicity and off-target toxicity inhibits the growth and metastasis of trastuzumab-resistant tumor cells.
Guo R; Zhang D; Zhang C; Yang Y; Liu H; Yang Y; Lin J
Int J Pharm; 2021 Oct; 608():121081. PubMed ID: 34506924
[TBL] [Abstract][Full Text] [Related]
9. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
10. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
11. TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma.
Onda M; Bruland ØS; Pastan I
Clin Orthop Relat Res; 2005 Jan; (430):142-8. PubMed ID: 15662316
[TBL] [Abstract][Full Text] [Related]
12. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
13. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
16. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
[TBL] [Abstract][Full Text] [Related]
17. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
[TBL] [Abstract][Full Text] [Related]
18. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
20. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]